34227-72-0
34227-72-0
Chemical Structure
C14 Ceramide
- CAS No.: 34227-72-0
- Formula:C32H63NO3
- Molecular Weight:509.85
IUPAC Name: N-((2S,3R,E)-1,3-dihydroxyoctadec-4-en-2-yl)tetradecanamide
InChIKey: ZKRPGPZHULJLKJ-JHRQRACZSA-N
SMILES: OC[C@@H]([C@@H](/C=C/CCCCCCCCCCCCC)O)NC(CCCCCCCCCCCCC)=O
Biological Activity: C14 Ceramide is an ester product.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
C14 Ceramide | 99.91% | C14 Ceramide is an ester product. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C12-Ceramide (Standard) | ≥98% | C12-Ceramide (Standard) is the analytical standard of C12-Ceramide. This product is intended for research and analytical applications. C12-Ceramide (N-Lauroyl-D-erythro-sphingosine), a naturally occurring ceramide, is formed by hydrolysis of C12 sphingomyelin. C12-Ceramide can enhance the Doxorubicin toxicity in MDA-MB-231 cells. C12-Ceramide also can be used to diagnose types A and B Niemann-Pick disease. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C16-Ceramide (d18:1/16:0) | 99.92% | C16-Ceramide (d18:1/16:0) is a natural small molecule activating p53 through the direct and selective binding. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18-Ceramide (d18:1/18:0) | 99.95% | C18-Ceramide (d18:1/18:0) is a bioactive molecule with multiple functions in cells, not a traditional agonist or inhibitor targeting a single site. It can act on multiple cellular targets, such as proteins related to endoplasmic reticulum stress (e.g., ATF-4, XBP-1, CHOP), proteins in the PI3K/AKT signaling pathway, and SNARE complex proteins. It exerts activities like inducing cell death, promoting autophagy, and regulating exocytosis through mechanisms such as activating endoplasmic reticulum stress, inhibiting the PI3K/AKT signaling pathway, and affecting lipid raft - related functions. It can be used in research on the mechanism of neuronal injury in the field of neuroscience and in the treatment research of cancers such as glioma in the field of oncology. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C17 Ceramide (d18:1/17:0) | 98.0% | C17 Ceramide (d18:1/17:0) (N-Heptadecanoyl-D-erythro-sphingosine) is a phospholipid internal standard. C17 Ceramide (d18:1/17:0) is used in studies of medium-chain acyl-CoA dehydrogenase deficiency (MCADD). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C16 Ceramide (d16:1,C16:0) | 98.0% | C16 Ceramide (d16:1,C16:0) is a bioactive sphingolipid that induces ordered- and gel-phase formation and thermal stabilization of palmitoylsphingomyelin-rich domains in palmitoylphosphocholine (POPC) bilayers. C16 Ceramide (d16:1,C16:0) is found in sphingomyelins in human erythrocytes. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C14 Ceramide (d18:1/14:0) | 99% | C14 Ceramide (d18:1/14:0) is an endogenous ceramide produced by ceramide synthetase 6, which can be used for Parkinson's and diabetes research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Octadecanoyl-L-erythro-sphingosine | Octadecanoyl-L-erythro-sphingosine is an ester product. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C15-Ceramide | 99.73% | C15-Ceramide is an ester product. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C16 Ceramide (d14:1/16:0) | C16 Ceramide (d14:1/16:0) is a ceramide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
C18 Ceramide (d17:1/18:0) | C18 Ceramide (d17:1/18:0) is a ceramide. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
